Symbols / IBO
IBO Chart
About
Impact BioMedical Inc. discovers, develops, and commercializes products and technologies to address unmet needs in human healthcare and wellness for specialty biopharmaceuticals, antivirals, antimicrobials, consumer healthcare, and wellness products in the United States. The company provides Linebacker, a platform of small molecule electrophilically enhanced polyphenol compounds with application in oncology, inflammatory disorders, and neurology; and Laetose technology that is derived from a unique combination of sugar and inositol, which can inhibit the inflammatory and metabolic response of sugar alone. It also develops functional fragrance formulation, a suite of functional fragrances containing specialized botanical ingredients with application as an antimicrobial, and as an additive in insect repellents, detergents, lotions, shampoo, fabrics, and other substances. In addition, the company develops Equivir/Equivir G technology, a novel blend of polyphenols, which have demonstrated antiviral effects for use in as health supplements and medications. Impact BioMedical Inc. was incorporated in 2018 and is based in Houston, Texas. Impact BioMedical Inc. operates as a subsidiary of DSS, Inc.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 46.03M |
| Enterprise Value | 71.92M | Income | -44.19M | Sales | 25.00K |
| Book/sh | -0.97 | Cash/sh | 12000.00 | Dividend Yield | — |
| Payout | 0.00% | Employees | 2 | IPO | — |
| P/E | — | Forward P/E | — | PEG | — |
| P/S | 1841.33 | P/B | -0.45 | P/C | — |
| EV/EBITDA | -23.01 | EV/Sales | 2876.73 | Quick Ratio | 0.00 |
| Current Ratio | 0.04 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -3.94 | EPS next Y | — | EPS Growth | — |
| Revenue Growth | — | Earnings | — | ROA | -7.68% |
| ROE | -3.47% | ROIC | — | Gross Margin | 92.00% |
| Oper. Margin | -52.67% | Profit Margin | 0.00% | Shs Outstand | 104.62M |
| Shs Float | 103.63M | Short Float | 2.07% | Short Ratio | 4.15 |
| Short Interest | — | 52W High | 6.17 | 52W Low | 0.36 |
| Beta | — | Avg Volume | 114.08K | Volume | 9.55K |
| Target Price | — | Recom | None | Prev Close | $0.44 |
| Price | $0.44 | Change | 0.00% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
—
Mean price target
2. Current target
$0.44
Latest analyst target
3. DCF / Fair value
$-0.44
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.44
Low
—
High
—
Mean
—
News
RSS: Latest IBO news- Announcement - In relation to the matter of IBO Technology Company Limited (In Liquidation) (incorporated in the Cayman Islands with limited liability) (Stock Code: 2708) Cancellation of listing - hkex.com.hk Wed, 03 Dec 2025 08
- Why Impact Biomedical Inc. (IBO) Surged On Thursday? - Yahoo Finance Fri, 21 Mar 2025 07
- Impact Biomedical stock soars after merger deal with Dr Ashleys - Investing.com Mon, 23 Jun 2025 07
- Why Ibotta Stock Soared in March 2025 - The Motley Fool Fri, 04 Apr 2025 07
- Top movers in Friday's after hours session - ChartMill Fri, 19 Dec 2025 08
- ImmunityBio stock set for volatile week after ANKTIVA sales jump and new trial update - TechStock² Sat, 17 Jan 2026 08
- Impact BioMedical’s Unexpected Stock Surge: Buy or Caution? - StocksToTrade ue, 01 Apr 2025 07
- Does Universal Ibogaine (CVE:IBO) Have A Healthy Balance Sheet? - simplywall.st hu, 12 Jun 2025 07
- IBO Stock Price and Chart — AMEX:IBO - TradingView ue, 17 Sep 2024 13
- DSS, Inc. Celebrates Impact BioMedical Inc.'s Successful IPO and Proudly Advances Shareholder Value - Stock Titan Mon, 16 Sep 2024 07
- Global IBO Group Ltd. a Unique and Integrated AIGC Animation Streaming Platform Announces Closing of Business Combination with Bukit Jalil Global Acquisition 1 Ltd. - Yahoo Finance hu, 08 May 2025 07
- Insider Sale: 10% owner at $IBO Sells 53,280 Shares - Intellectia AI ue, 25 Mar 2025 07
- Impact BioMedical (IBO) Soars: A Financial Analysis of Its Recent Surge - Investing.com India ue, 24 Jun 2025 07
- Dr Ashleys Limited and Impact BioMedical Inc. Announce Strategic Merger - GlobeNewswire Mon, 23 Jun 2025 07
- Where to buy Legend of Zelda amiibo - Polygon hu, 24 Apr 2025 07
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 161000 | 88006 | — | Sale at price 0.54 - 0.55 per share. | DSS INC. | Beneficial Owner of more than 10% of a Class of Security | — | 2025-05-27 00:00:00 | D |
| 1 | 1689693 | 996397 | — | Sale at price 0.46 - 0.96 per share. | CHAN HENG FAI AMBROSE | Director and Beneficial Owner of more than 10% of a Class of Security | — | 2025-04-04 00:00:00 | I |
| 2 | 890800 | 845013 | — | Sale at price 0.95 per share. | DSS INC. | Beneficial Owner of more than 10% of a Class of Security | — | 2025-04-04 00:00:00 | D |
| 3 | 351555 | 174020 | — | Sale at price 0.50 per share. | CHAN HENG FAI AMBROSE | Director | — | 2025-04-03 00:00:00 | I |
| 4 | 2526918 | 2199273 | — | Sale at price 0.82 - 1.03 per share. | CHAN HENG FAI AMBROSE | Director and Beneficial Owner of more than 10% of a Class of Security | — | 2025-04-01 00:00:00 | I |
| 5 | 605620 | 2726169 | — | Sale at price 2.20 - 4.96 per share. | DSS INC. | Beneficial Owner of more than 10% of a Class of Security | — | 2025-03-27 00:00:00 | D/I |
| 6 | 200 | 416 | — | Purchase at price 2.08 per share. | DSS INC. | Beneficial Owner of more than 10% of a Class of Security | — | 2025-03-20 00:00:00 | I |
| 7 | 53300 | 110880 | — | Sale at price 2.08 - 2.90 per share. | DSS INC. | Beneficial Owner of more than 10% of a Class of Security | — | 2025-03-20 00:00:00 | I |
| 8 | 500 | 1129 | — | Purchase at price 2.26 per share. | HEUSZEL FRANK D. | Chief Executive Officer | — | 2024-12-05 00:00:00 | D |
| 9 | 500 | 1305 | — | Purchase at price 2.61 per share. | HEUSZEL FRANK D. | Chief Executive Officer | — | 2024-11-27 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | -5.32M | 0.00 | -323.90K | -323.90K |
| TaxRateForCalcs | 0.21 | 0.00 | 0.08 | 0.08 |
| NormalizedEBITDA | 2.80M | -2.84M | -2.20M | -2.20M |
| TotalUnusualItems | -25.36M | 0.00 | -4.10M | -4.10M |
| TotalUnusualItemsExcludingGoodwill | -25.36M | 0.00 | -4.10M | -4.10M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -24.71M | -4.34M | -7.05M | -7.05M |
| ReconciledDepreciation | 1.12M | 1.12M | 1.11M | 1.11M |
| EBITDA | -22.55M | -2.84M | -6.30M | -6.30M |
| EBIT | -23.67M | -3.96M | -7.41M | -7.41M |
| NetInterestIncome | -1.05M | -431.00K | -438.00K | -438.00K |
| InterestExpense | 1.06M | 444.00K | 462.00K | 462.00K |
| InterestIncome | 13.00K | 13.00K | 24.00K | 24.00K |
| NormalizedIncome | -4.68M | -4.34M | -3.27M | -3.27M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -24.71M | -4.34M | -7.05M | -7.05M |
| TotalExpenses | 3.40M | 4.03M | 3.45M | 3.45M |
| RentExpenseSupplemental | 32.00K | 0.00 | ||
| TotalOperatingIncomeAsReported | -28.75M | -4.03M | -3.40M | -3.40M |
| DilutedAverageShares | 10.76M | 60.25M | 11.50M | 60.25M |
| BasicAverageShares | 10.76M | 60.25M | 11.50M | 11.50M |
| DilutedEPS | -2.30 | -0.07 | -0.61 | -0.61 |
| BasicEPS | -2.30 | -0.07 | -0.61 | -0.61 |
| DilutedNIAvailtoComStockholders | -24.71M | -4.34M | -7.05M | -7.05M |
| NetIncomeCommonStockholders | -24.71M | -4.34M | -7.05M | -7.05M |
| NetIncome | -24.71M | -4.34M | -7.05M | -7.05M |
| MinorityInterests | 62.00K | 71.00K | 204.00K | 204.00K |
| NetIncomeIncludingNoncontrollingInterests | -24.77M | -4.41M | -7.25M | -7.25M |
| NetIncomeContinuousOperations | -24.77M | -4.41M | -7.25M | -7.25M |
| TaxProvision | 33.00K | 0.00 | -621.00K | -621.00K |
| PretaxIncome | -24.74M | -4.41M | -7.88M | -7.88M |
| OtherIncomeExpense | -20.29M | 52.00K | -4.03M | -4.03M |
| OtherNonOperatingIncomeExpenses | 5.07M | 52.00K | 66.00K | 66.00K |
| SpecialIncomeCharges | -25.36M | 0.00 | -4.10M | -4.10M |
| WriteOff | 0.00 | 4.10M | 4.10M | |
| ImpairmentOfCapitalAssets | 25.36M | 0.00 | ||
| NetNonOperatingInterestIncomeExpense | -1.05M | -431.00K | -438.00K | -438.00K |
| InterestExpenseNonOperating | 1.06M | 444.00K | 462.00K | 462.00K |
| InterestIncomeNonOperating | 13.00K | 13.00K | 24.00K | 24.00K |
| OperatingIncome | -3.40M | -4.03M | -3.40M | -3.40M |
| OperatingExpense | 3.40M | 4.03M | 3.45M | 3.45M |
| OtherOperatingExpenses | 171.00K | 119.00K | 68.00K | 68.00K |
| DepreciationAmortizationDepletionIncomeStatement | 1.12M | 1.12M | 1.11M | 1.11M |
| DepreciationAndAmortizationInIncomeStatement | 1.12M | 1.12M | 1.11M | 1.11M |
| Amortization | 1.12M | 1.11M | 1.11M | |
| AmortizationOfIntangiblesIncomeStatement | 1.12M | 1.11M | 1.11M | |
| ResearchAndDevelopment | 278.00K | 1.69M | 1.23M | 1.23M |
| SellingGeneralAndAdministration | 1.83M | 1.10M | 1.05M | 1.05M |
| SellingAndMarketingExpense | 633.00K | 65.00K | 325.00K | 325.00K |
| GeneralAndAdministrativeExpense | 1.20M | 1.04M | 1.05M | 1.05M |
| OtherGandA | 1.16M | 1.04M | 1.05M | 1.05M |
| RentAndLandingFees | 32.00K | 0.00 | ||
| TotalRevenue | 0.00 | 0.00 | 50.00K | 50.00K |
| OperatingRevenue | 0.00 | 0.00 | 50.00K | 50.00K |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 11.50M | 11.50M | 11.50M | 11.50M |
| ShareIssued | 11.50M | 11.50M | 11.50M | 11.50M |
| NetDebt | 6.88M | 12.07M | 9.99M | 12.48M |
| TotalDebt | 8.88M | 12.07M | 9.99M | 12.52M |
| TangibleBookValue | -13.61M | -18.85M | -15.57M | -9.63M |
| InvestedCapital | 13.08M | 37.24M | 39.55M | 49.13M |
| WorkingCapital | -7.34M | -12.80M | -10.47M | -12.36M |
| NetTangibleAssets | -13.55M | -18.79M | -15.57M | -9.63M |
| CommonStockEquity | 4.20M | 25.16M | 29.56M | 36.61M |
| PreferredStockEquity | 60.00K | 60.00K | ||
| TotalCapitalization | 4.26M | 25.22M | 29.56M | 36.61M |
| TotalEquityGrossMinorityInterest | 7.24M | 28.26M | 32.67M | 39.92M |
| MinorityInterest | 2.98M | 3.04M | 3.11M | 3.31M |
| StockholdersEquity | 4.26M | 25.22M | 29.56M | 36.61M |
| RetainedEarnings | -37.67M | -12.96M | -8.62M | -1.57M |
| AdditionalPaidInCapital | 41.86M | 38.11M | 38.11M | 38.06M |
| CapitalStock | 71.00K | 70.00K | 70.00K | 125.00K |
| CommonStock | 11.00K | 10.00K | 70.00K | 125.00K |
| PreferredStock | 60.00K | 60.00K | 0.00 | |
| TotalLiabilitiesNetMinorityInterest | 13.05M | 16.37M | 13.83M | 16.50M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 3.27M | 3.23M | 3.23M | 3.86M |
| NonCurrentDeferredLiabilities | 3.27M | 3.23M | 3.23M | 3.86M |
| NonCurrentDeferredTaxesLiabilities | 3.27M | 3.23M | 3.23M | 3.86M |
| CurrentLiabilities | 9.79M | 13.14M | 10.59M | 12.64M |
| CurrentDebtAndCapitalLeaseObligation | 8.88M | 12.07M | 9.99M | 12.52M |
| CurrentDebt | 8.88M | 12.07M | 9.99M | 12.52M |
| CurrentNotesPayable | 8.88M | 12.07M | 9.99M | 12.52M |
| PayablesAndAccruedExpenses | 907.00K | 1.06M | 602.00K | 121.00K |
| CurrentAccruedExpenses | 194.00K | 230.00K | 63.00K | 6.00K |
| Payables | 713.00K | 832.00K | 539.00K | 115.00K |
| AccountsPayable | 713.00K | 832.00K | 539.00K | 115.00K |
| TotalAssets | 20.29M | 44.63M | 46.50M | 56.42M |
| TotalNonCurrentAssets | 17.84M | 44.30M | 46.38M | 56.14M |
| OtherNonCurrentAssets | 782.00K | 4.82M | ||
| NonCurrentNoteReceivables | 17.00K | 0.00 | 190.00K | 5.08M |
| InvestmentsAndAdvances | 0.00 | 782.00K | 4.82M | |
| OtherInvestments | 0.00 | 782.00K | ||
| LongTermEquityInvestment | 782.00K | 4.82M | ||
| InvestmentsInOtherVenturesUnderEquityMethod | 782.00K | 4.82M | ||
| GoodwillAndOtherIntangibleAssets | 17.81M | 44.01M | 45.13M | 46.24M |
| OtherIntangibleAssets | 17.81M | 18.92M | 20.03M | 21.15M |
| Goodwill | 0.00 | 25.09M | 25.09M | 25.09M |
| NetPPE | 17.00K | 287.00K | 276.00K | 0.00 |
| AccumulatedDepreciation | -13.00K | -6.00K | 0.00 | 0.00 |
| GrossPPE | 30.00K | 293.00K | 276.00K | 0.00 |
| ConstructionInProgress | 0.00 | 263.00K | 251.00K | 0.00 |
| MachineryFurnitureEquipment | 30.00K | 30.00K | 25.00K | 0.00 |
| CurrentAssets | 2.45M | 332.00K | 122.00K | 287.00K |
| OtherCurrentAssets | 104.00K | 1.00K | ||
| PrepaidAssets | 265.00K | 0.00 | 61.00K | 43.00K |
| Receivables | 184.00K | 331.00K | 16.00K | 197.00K |
| OtherReceivables | 128.00K | |||
| NotesReceivable | 184.00K | 203.00K | 16.00K | 197.00K |
| CashCashEquivalentsAndShortTermInvestments | 2.00M | 1.00K | 2.00K | 46.00K |
| CashAndCashEquivalents | 2.00M | 1.00K | 2.00K | 46.00K |
| CashFinancial | 2.00M | 1.00K |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -3.92M | -2.87M | -2.52M | -2.52M |
| IssuanceOfDebt | 2.19M | 2.87M | 2.55M | 2.55M |
| IssuanceOfCapitalStock | 3.73M | 0.00 | ||
| CapitalExpenditure | -18.00K | -276.00K | -276.00K | |
| EndCashPosition | 2.00M | 1.00K | 2.00K | 2.00K |
| BeginningCashPosition | 1.00K | 2.00K | 46.00K | 46.00K |
| ChangesInCash | 2.00M | -1.00K | -44.00K | -44.00K |
| FinancingCashFlow | 5.92M | 2.87M | 2.55M | 2.55M |
| CashFlowFromContinuingFinancingActivities | 5.92M | 2.87M | 2.55M | 2.55M |
| NetCommonStockIssuance | 3.73M | 0.00 | ||
| CommonStockIssuance | 3.73M | 0.00 | ||
| NetIssuancePaymentsOfDebt | 2.19M | 2.87M | 2.55M | 2.55M |
| NetShortTermDebtIssuance | 2.19M | 2.87M | 2.55M | 2.55M |
| ShortTermDebtIssuance | 2.19M | 2.87M | 2.55M | 2.55M |
| InvestingCashFlow | 2.00K | -15.00K | -349.00K | -349.00K |
| CashFlowFromContinuingInvestingActivities | 2.00K | -15.00K | -349.00K | -349.00K |
| NetOtherInvestingChanges | 2.00K | 3.00K | -8.00K | -8.00K |
| NetInvestmentPurchaseAndSale | 0.00 | -65.00K | -65.00K | |
| PurchaseOfInvestment | 0.00 | -65.00K | -65.00K | |
| NetPPEPurchaseAndSale | 0.00 | -18.00K | -276.00K | -276.00K |
| PurchaseOfPPE | 0.00 | -18.00K | -276.00K | -276.00K |
| OperatingCashFlow | -3.92M | -2.85M | -2.24M | -2.24M |
| CashFlowFromContinuingOperatingActivities | -3.92M | -2.85M | -2.24M | -2.24M |
| ChangeInWorkingCapital | -608.00K | 436.00K | 421.00K | 421.00K |
| ChangeInPayablesAndAccruedExpense | -471.00K | 460.00K | 481.00K | 481.00K |
| ChangeInAccruedExpense | -35.00K | 167.00K | 57.00K | 57.00K |
| ChangeInPayable | -436.00K | 293.00K | 424.00K | 424.00K |
| ChangeInAccountPayable | -436.00K | 293.00K | 424.00K | 424.00K |
| ChangeInPrepaidAssets | -265.00K | 104.00K | -60.00K | -60.00K |
| ChangeInReceivables | 128.00K | -128.00K | 0.00 | 0.00 |
| OtherNonCashItems | -5.07M | |||
| StockBasedCompensation | 19.00K | 0.00 | ||
| AssetImpairmentCharge | 25.36M | 0.00 | 4.10M | 4.10M |
| DeferredTax | 33.00K | 0.00 | -621.00K | -621.00K |
| DeferredIncomeTax | 33.00K | 0.00 | -621.00K | -621.00K |
| DepreciationAmortizationDepletion | 1.12M | 1.12M | 1.11M | 1.11M |
| DepreciationAndAmortization | 1.12M | 1.12M | 1.11M | 1.11M |
| AmortizationCashFlow | 1.11M | 1.11M | ||
| AmortizationOfIntangibles | 1.11M | 1.11M | ||
| NetIncomeFromContinuingOperations | -24.77M | -4.41M | -7.25M | -7.25M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for IBO
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|